Altamira Therapeutics Ltd. (CYTO)

1.4500 -0.0300 (-2.03%) At close: 04:00PM EDT

Altamira Therapeutics Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
441 295 5950
https://altamiratherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Thomas Meyer Ph.D.	Founder, President, Chairman, CEO & MD	569.82k	N/A	1968
Mr. Marcel Gremaud CPA	Chief Financial Officer	N/A	N/A	1959
Dr. Covadonga Paneda	Chief Operating Officer	N/A	N/A	1974
Dr. Samuel A. Wickline M.D.	Chief Scientific Adviser	N/A	N/A	1953

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Corporate governance

Altamira Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.